MALVERN, PA & TOKYO, Japan — H.U. Group Holdings Inc. and its subsidiary Fujirebio Holdings, Inc., have announced that Fujirebio Diagnostics, Inc. has acquired Plasma Services Group, Inc. (PSG), a specialized provider of rare biological materials for the in vitro diagnostics (IVD) and life sciences industries. The terms of the transaction were not disclosed.
Founded in 2004, Plasma Services Group has built a strong reputation in the collection, screening, and supply of high-quality and rare biological samples from its FDA-registered, ISO-certified facility in Moorestown, New Jersey. The company supports global scientific research and development, particularly in the field of rare diseases, by offering biological materials used in control reagents and calibrators.
This acquisition positions Fujirebio Diagnostics to expand its capabilities and deepen its footprint in the IVD landscape. “We are excited to welcome Plasma Services Group, a company that has gained a solid reputation as a reliable global supplier of difficult-to-obtain biological raw materials to the life sciences industry, to the Fujirebio group of companies,” said Goki Ishikawa, President & CEO of Fujirebio Holdings, Inc. “Current and future IVD and life science partners of Fujirebio and Plasma Services Group will benefit from the synergies in our combined offer of rare samples and biological materials, which in turn further reinforce Fujirebio’s position in the market as a trusted CDMO partner.”
The partnership brings together PSG’s expertise and responsiveness with Fujirebio’s global reach and innovation in diagnostics. “For over 20 years, our mission at PSG has always been rooted in serving our customers with care, integrity, and a commitment to quality,” said Nichelle Fernandez, President of Plasma Services Group. “This next chapter with Fujirebio is deeply meaningful. It allows us to stay true to who we are while preserving the personal, responsive service our customers value. Together, we’re positioned to offer even stronger support for the scientists and innovators who rely on us. Our shared commitment to consistency will have a lasting impact across the global IVD landscape.”
The acquisition strengthens Fujirebio’s role as a leading partner in the diagnostics space, building on PSG’s legacy of providing rare and specialized materials, and opens new avenues for advancing research and manufacturing in the life sciences sector.
Houlihan Lokey served as the exclusive financial advisor to Fujirebio, while Achelous Partners represented PSG.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.